Taken together, this analysis confirmed that we successfully reprogrammed somatic cells from patients with mutations in FUS and TDP-43, generating bona fide patient-specific iPSCs (ALS-iPSCs). The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.